New Releases from NCBI BookshelfPolatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-141 [Internet].​Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-141 [Internet].